First of its kind pancreatic cancer trial to begin in Scotland
Published: 25 April 2018
A ground-breaking new pancreatic cancer trial, which aims to match patients with more targeted and effective treatment for their tumours, is to begin in Scotland.
A ground-breaking new pancreatic cancer trial, which aims to match patients with more targeted and effective treatment for their tumours, is to begin in Scotland. Run by Precision-Panc, a research programme and clinical trials project led by the University of Glasgow and majority-funded by Cancer Research UK, the trial will bring a precision medicine approach to pancreatic cancer treatment for the first time in the UK.
Professor Andrew Biankin, Chief Investigator of this project, Regius Chair of Surgery and Director of the University of Glasgow’s Wolfson Wohl Cancer Research Centre, said: “This is an extraordinary opportunity to transform the therapeutic options and treatment pathway for pancreatic cancer patients. It is one of the first projects in the UK to bring genetic sequencing into the clinic in order to direct the care of pancreatic cancer patients.”
First published: 25 April 2018